Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450106 · ClinicalTrials.gov registry record · Phase 1

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

A Phase 1 study of Prostate Cancer, sponsored by SURGE Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
4
Study locations

NCT06450106 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by SURGE Therapeutics. The registered enrollment target is 18 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450106, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by SURGE Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
4
Study locations

Study Summary

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Conditions Studied

Prostate Cancer

Interventions

  • DRUG STM-416p

Study Locations (4)

Victoria

  • Australian Prostate Center - Melbourne N.
  • Epworth HealthCare - Melbourne N.

Arizona

  • Arizona Urology Specialists - Tucson

Florida

  • University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2025-05-08
Est. Completion 2026-12
Phase Phase 1

Sponsor

SURGE Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06450106

The ClinicalTrials.gov registry entry for NCT06450106 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The listed sponsor is SURGE Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which STM-416p is the first listed.

NCT06450106 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Victoria, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT06450106 about?

NCT06450106 is a clinical study titled "Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy". A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

What is the current status of trial NCT06450106?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-05-08. Estimated completion is 2026-12.

What conditions does trial NCT06450106 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06450106?

The interventions under investigation include: STM-416p (DRUG).

Who is sponsoring clinical trial NCT06450106?

This trial is sponsored by SURGE Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06450106 being conducted?

This trial has 4 study locations across Arizona, Florida, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.